NCT01716806 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL) (NCT01716806)

Trial Description
This is an open-label, multicenter, phase 2 clinical trial designed to evaluate the efficacy and safety of the antibody-drug conjugate brentuximab vedotin as a single-agent (Part A) and in combination with dacarbazine (Part B) or bendamustine (Part C) in front-line therapy of Hodgkin lymphoma in adults age 60 and above.

This trial is sponsored by Seattle Genetics. [1]

Study Data

Study Schematic 

NCT01716806 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.